{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:29:46Z","timestamp":1794450586390,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"DOI":"10.2146\/ajhp130571","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T16:50:52Z","timestamp":1397494252000},"page":"722-727","source":"Crossref","is-referenced-by-count":20,"title":["Investigation of pegloticase-associated adverse events from a nationwide reporting system database"],"prefix":"10.1093","volume":"71","author":[{"given":"William M.","family":"Gentry","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Dotson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hartley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R.","family":"Stafford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bottorff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, South College, Knoxville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041211003270600_b1-0710722","unstructured":"Savient Pharmaceuticals. What is refractory chronic gout (RCG)?www.krystexxa.com\/about_refractory_chronic_gout.aspx (accessed 2013 Aug 30)."},{"key":"2019041211003270600_b2-0710722","first-page":"63","article-title":"Critical appraisal of the role of pegloticase in the management of gout","volume":"4","author":"Ea","year":"2012","journal-title":"Open Access Rheumatol Res Rev"},{"key":"2019041211003270600_b3-0710722","unstructured":"Food and Drug Administration. Krystexxa (pegloticase) for intravenous infusion. Briefing document for arthritis advisory committee. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM165814.pdf (accessed 2013 Aug 30)."},{"key":"2019041211003270600_b4-0710722","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2019041211003270600_b5-0710722","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part II: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2019041211003270600_b6-0710722","unstructured":"Savient Pharmaceuticals. Savient Pharmaceuticals announces permanent J-code assigned for Krystexxa. http:\/\/investor.savient.com\/releasedetail.cfm?ReleaseID=637527 (accessed 2013 Nov 10)."},{"key":"2019041211003270600_b7-0710722","unstructured":"Waknine\n              Y\n            \n          . FDA approves pegloticase for refractory gout. www.medscape.com\/viewarticle\/728557 (accessed 2013 Nov 10)."},{"key":"2019041211003270600_b8-0710722","unstructured":"Savient Pharmaceuticals. Krystexxa (pegloticase). Phase 3 clinical trial data, secondary endpoint\u2014tophus resolution. www.krystexxa.com\/hcp\/tophus_response.aspx (accessed 2013 Nov 10)."},{"key":"2019041211003270600_b9-0710722","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"2019041211003270600_b10-0710722","volume-title":"Safety and efficacy of long-term pegloticase (Krystexxa) treatment in adult patients with chronic gout refractory to conventional therapy","author":"Hamburger"},{"key":"2019041211003270600_b11-0710722","unstructured":"Food and Drug Administration. Risk evaluation and mitigation strategy (REMS) for Krystexxa (pegloticase). www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM227955.pdf (accessed 2013 Aug 30)."},{"issue":"suppl 7","key":"2019041211003270600_b12-0710722","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.2146\/ajhp090461","article-title":"Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems","volume":"66","author":"Shane","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041211003270600_b13-0710722","unstructured":"Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) (formerly AERS). www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm (accessed 2013 Aug 30)."},{"key":"2019041211003270600_b14-0710722","unstructured":"Savient Pharmaceuticals. Krystexxa (pegloticase). Highlights of prescribing information. www.savientpharma.com\/pdf\/KRYSTEXXA%20Prescribing%20Information.pdf (accessed 2013 Aug 30)."},{"key":"2019041211003270600_b15-0710722","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.semarthrit.2012.11.002","article-title":"Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA Adverse Event Reporting System database","volume":"42","author":"Gandhi","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2019041211003270600_b16-0710722","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Noren","year":"2006","journal-title":"Stat Med"},{"key":"2019041211003270600_b17-0710722","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019041211003270600_b18-0710722","unstructured":"Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacovigilance assessment. www.fda.gov\/downloads\/regulatoryinformation\/guidances\/ucm126834.pdf (accessed 2013 Nov 10)."},{"key":"2019041211003270600_b19-0710722","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1001\/jama.2011.1616","article-title":"Pegloticase and chronic gout","volume":"306","author":"Ea","year":"2011","journal-title":"JAMA"},{"key":"2019041211003270600_b20-0710722","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0269881108100776","article-title":"Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy","volume":"24","author":"Ratcliffe","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2019041211003270600_b21-0710722","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2019041211003270600_b22-0710722","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pds.1275","article-title":"Reports of hyperkalemia after publication of RALES\u2014a pharmacovigilance study","volume":"15","author":"Hauben","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/9\/722\/28372559\/ajhp0722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:48:06Z","timestamp":1555102086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/9\/722\/5111251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130571","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727303300.793528703","asserted-by":"object"}]},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,1]]},"published":{"date-parts":[[2014,5,1]]}}}